GSK — GSK plc

GSK Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Sales: Increased by 7% to over GBP 32 billion, driven primarily by Specialty Medicines (+17%).
• Core Operating Profit: Grew by 11%.
• Earnings Per Share (EPS): Increased by 12%.
• Cash Generation: Strong performance with GBP 8.9 billion, supporting a dividend increase from 64p to 66p.
• Operating Margin: Improved by 110 basis points to 29.9%.
• Free Cash Flow: Rose to GBP 4 billion, or over GBP 5 billion excluding Zantac payments.

2. Strategic Updates and Business Highlights

• R&D Progress: Achieved 5 FDA approvals and initiated 7 pivotal trials. Key focus areas include oncology and respiratory diseases.
• Specialty Medicines: Continued strong performance, particularly in respiratory (Nucala +18%, Benlysta +22%) and oncology (Jemperli +89%).
• Vaccines: Sales of GBP 9.2 billion, up 2%, with Shingrix performing well in Europe and international markets.
• HIV Portfolio: Long-acting injectables driving growth, with plans for Q6M treatment regimen selection expected mid-2026.
• Business Development: Acquisition of Rapp Therapeutics to enhance pipeline with a focus on food allergies.

3. Forward Guidance and Outlook

• 2026 Sales Growth: Expected to be between 3% to 5%; core operating profit and EPS projected to grow by 7% to 9%.
• Specialty Medicines: Anticipated low double-digit growth, with mid- to high single-digit growth for HIV.
• Vaccines and GenMed: Expected to see low single-digit decline to stable performance.
• Operational Focus: Emphasis on simplifying operations and enhancing product-centric strategies.

4. Bad News, Challenges, or Points of Concern

• Zantac Payments: GBP 1.2 billion paid in 2025, with total payments of GBP 1.9 billion, although the settlement process is nearing completion.
• Competitive Pressures: Declining sales for ZEJULA due to FDA labeling restrictions; potential headwinds from currency fluctuations impacting sales and operating profit.
• Market Dynamics: Slower ramp-up expected for new products like BLENREP due to the need for coordination with eye care professionals.

5. Notable Q&A Insights

• Oncology Strategy: There are overlapping products in development for COPD and asthma, with a focus on differentiating their roles in treatment.
• HIV Market: Anticipated significant market share growth with the introduction of Q6M treatment, expected to capture up to 50% of patients willing to switch to long-acting injectables.
• BLENREP Launch: Initial uptake is slower due to the REMS program, but positive feedback from physicians indicates a promising trajectory.
• R&D Staffing: A reduction of 350 staff in R&D was noted, raising questions about broader restructuring efforts.
• Financial Transparency: GSK plans to provide more detailed updates on strategy and financials in future calls, with a commitment to clear communication on progress and challenges.

Overall, GSK reported a strong performance in 2025 with positive growth across key areas, while also addressing potential challenges and strategic shifts for the coming year.